4//SEC Filing
Roberts Zachary 4
Accession 0001593968-23-000525
CIK 0001737287other
Filed
Mar 23, 8:00 PM ET
Accepted
Mar 24, 8:16 PM ET
Size
5.1 KB
Accession
0001593968-23-000525
Insider Transaction Report
Form 4
Roberts Zachary
EVP of R&D
Transactions
- Award
Common Stock
2023-03-22+148,035→ 399,943 total
Footnotes (1)
- [F1]Represents performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.
Documents
Issuer
Allogene Therapeutics, Inc.
CIK 0001737287
Entity typeother
Related Parties
1- filerCIK 0001851044
Filing Metadata
- Form type
- 4
- Filed
- Mar 23, 8:00 PM ET
- Accepted
- Mar 24, 8:16 PM ET
- Size
- 5.1 KB